Recursion Pharmaceuticals
RXRX
334 hedge funds and large institutions have $1.57B invested in Recursion Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 114 increasing their positions, 89 reducing their positions, and 59 closing their positions.
36% more call options, than puts
Call options by funds: $55.7M | Put options by funds: $41M
28% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 89
11% more capital inflows, than outflows
Capital inflows: $118M | Capital outflows: $107M
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.24% less ownership
Funds ownership: 77.87% → 77.63% (-0.24%)
5% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 59
1% less funds holding
Funds holding: 338 → 334 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.6M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.55M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.68M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$4.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.36M |
| 2 |
ARK Investment Management
St. Petersburg,
Florida
|
-$8.97M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$8.81M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$8.27M |
| 5 |
Laurion Capital Management
New York
|
-$8.19M |
RXRX Hedge Fund Activity: Q2 2025 in Review
334 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2025, worth a combined $1.57B — down 3.5% from $1.63B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of RXRX and 56 opened new positions — a net loss of 3 holders — while 89 trimmed existing stakes and 114 added.
The largest buyer was BlackRock, adding an estimated $23.9M. The largest seller was State Street, cutting an estimated $9.36M.
- 334 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2025, down from 338 in Q1 2025.
- Funds reported $1.57B of Recursion Pharmaceuticals stock for Q2 2025, down 3.5% quarter-over-quarter.
- 56 funds opened new Recursion Pharmaceuticals positions in Q2 2025 and 59 closed out, a net change of -3 holders.
- The largest Recursion Pharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $23.9M added.
- The largest Recursion Pharmaceuticals seller in Q2 2025 was State Street, an estimated $9.36M sold.
Based on aggregated 13F filings for Q2 2025.